Alnylam Pharmaceuticals, Inc.(ALNY), an RNAi therapeutics company, on Thursday reported a net income for the first quarter of fiscal 2026, supported by a surge in revenue, driven by net product revenues.
Yvonne Greenstreet, CEO of Alnylam, said: "2026 is off to a strong start for Alnylam with the end of the first quarter marking one year since the U.S. launch of AMVUTTRA for ATTR-CM, and also representing a significant financial milestone with the achievement of over $1 billion in quarterly product revenues for the first time in our history."
For the three-month period to March 31, the drugmaker reported a net income of $205.991 million, compared with a net loss of $18.251 million in the same period last year. Net profit per share stood at $1.51 as against a net loss of $0.14 per share a year ago. Excluding items, earnings were $273.038 million, or $1.99 per share, compared with $37.941 billion, or $0.29 per share, last year.
Income from operations surged to $268.636 million from $18.077 million in the previous year.
Total revenue was $1.167 billion, up from $594.189 million in the previous year. Net product revenues jumped to $1.036 billion from $468.538 million last year. Revenue from AMVUTTRA was $889.931 million, higher than $309.992 million a year ago.
Looking ahead for fiscal 2026, Alnylam has reaffirmed total net product revenue guidance of $4.900 billion to $5.300 billion, up 64% to 77% from last year.
ALNY was up by 8.57% at $327 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.